Experimental lung cancer vaccine shows early promise in small trial

NCT ID NCT04432207

First seen Mar 26, 2026 · Last updated Apr 28, 2026 · Updated 4 times

Summary

This early-phase study tested a new immunotherapy called IMU-201 in 24 adults with advanced non-small cell lung cancer. The treatment aims to help the body's immune system fight cancer by targeting a protein called PD-1. Some participants received IMU-201 alone, while others got it combined with standard drugs. The study was stopped early, but researchers were checking for safety and signs of tumor shrinkage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cabrini Malvern Hospital

    Melbourne, Victoria, 3000, Australia

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, 2050, Australia

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • Macquarie University

    Macquarie, New South Wales, 2109, Australia

  • Mayo Clinic

    Phoenix, Arizona, 85054, United States

  • Ohio State University Medical Center

    Columbus, Ohio, 43210, United States

Conditions

Explore the condition pages connected to this study.